mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells

[1]  Aaron M. Rosenfeld,et al.  Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses , 2022, Immunity.

[2]  D. Czerwinski,et al.  Intratumoral immunotherapy relies on B and T cell collaboration , 2022, Science Immunology.

[3]  Aaron M. Rosenfeld,et al.  Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses , 2021, Immunity.

[4]  James E. Dahlman,et al.  Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs , 2021, Nature Biomedical Engineering.

[5]  Kimberly J. Hassett,et al.  Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Rachel S. Riley,et al.  Ionizable lipid nanoparticles for in utero mRNA delivery , 2021, Science Advances.

[7]  J. Gartner,et al.  mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. , 2020, The Journal of clinical investigation.

[8]  X. Saelens,et al.  The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of Administration , 2020, Molecular therapy. Nucleic acids.

[9]  T. Ishida,et al.  PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: faster PEG shedding attenuates anti-PEG IgM production. , 2020, International journal of pharmaceutics.

[10]  J. Szebeni,et al.  Anti-PEG antibodies: Properties, formation and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. , 2020, Advanced drug delivery reviews.

[11]  J. Utikal,et al.  An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma , 2020, Nature.

[12]  Jianyou Shi,et al.  Antibodies against polyethylene glycol in human blood: A literature review. , 2020, Journal of pharmacological and toxicological methods.

[13]  Rita Kundu,et al.  Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy , 2020, Frontiers in Microbiology.

[14]  Ö. Türeci,et al.  HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory , 2019, Oncoimmunology.

[15]  K. Burke,et al.  Accelerated Blood Clearance of Lipid Nanoparticles Entails a Biphasic Humoral Response of B-1 Followed by B-2 Lymphocytes to Distinct Antigenic Moieties , 2019, ImmunoHorizons.

[16]  M. Amiji,et al.  The role of surface chemistry in serum protein corona-mediated cellular delivery and gene silencing with lipid nanoparticles. , 2019, Nanoscale.

[17]  Kimberly J. Hassett,et al.  Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines , 2019, Molecular therapy. Nucleic acids.

[18]  A. Shimabukuro-Vornhagen,et al.  B Cell-Based Cancer Immunotherapy , 2019, Transfusion Medicine and Hemotherapy.

[19]  G. Storm,et al.  A Novel Platform for Cancer Vaccines: Antigen-Selective Delivery to Splenic Marginal Zone B Cells via Repeated Injections of PEGylated Liposomes , 2018, The Journal of Immunology.

[20]  M. V. van Loenen,et al.  Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile in situ , 2018, bioRxiv.

[21]  H. Hammad,et al.  Dendritic Cell Targeting mRNA Lipopolyplexes Combine Strong Antitumor T-Cell Immunity with Improved Inflammatory Safety. , 2018, ACS nano.

[22]  Lennart Lindfors,et al.  Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles , 2018, Proceedings of the National Academy of Sciences.

[23]  Robert Langer,et al.  Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. , 2017, Nano letters.

[24]  I. Verma,et al.  Systemic delivery of factor IX messenger RNA for protein replacement therapy , 2017, Proceedings of the National Academy of Sciences.

[25]  G. Vanham,et al.  Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  D. McNeel,et al.  B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines , 2016, Oncotarget.

[27]  P. Cullis,et al.  Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[28]  Özlem Türeci,et al.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.

[29]  C. Heirman,et al.  Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon , 2016, Molecular therapy. Nucleic acids.

[30]  R. Langer,et al.  mRNA vaccine delivery using lipid nanoparticles. , 2016, Therapeutic delivery.

[31]  D. Weissman,et al.  Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[32]  Daniel G. Anderson,et al.  Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs. , 2015, Nano letters.

[33]  T. Ishida,et al.  Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells. , 2015, Immunobiology.

[34]  H. Harashima,et al.  Molecular Tuning of a Vitamin E-Scaffold pH-Sensitive and Reductive Cleavable Lipid-like Material for Accelerated in Vivo Hepatic siRNA Delivery. , 2015, ACS biomaterials science & engineering.

[35]  C. Figdor,et al.  Long-lasting multifunctional CD8+ T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination , 2015, Oncoimmunology.

[36]  A. Akinc,et al.  Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy , 2014, Molecular therapy. Nucleic acids.

[37]  M. Heise,et al.  Acute and Chronic B Cell Depletion Disrupts CD4+ and CD8+ T Cell Homeostasis and Expansion during Acute Viral Infection in Mice , 2014, The Journal of Immunology.

[38]  H. Koblish,et al.  Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.

[39]  Jean Daudelin,et al.  CD40-Activated B Cells Can Efficiently Prime Antigen-Specific Naïve CD8+ T Cells to Generate Effector but Not Memory T cells , 2012, PloS one.

[40]  J. Borovička,et al.  Polyfunctional HCV‐specific T‐cell responses are associated with effective control of HCV replication , 2008, European journal of immunology.

[41]  B. Neyns,et al.  Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  J. Dai,et al.  Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. , 2008, Cytokine & growth factor reviews.

[43]  Taro Shimizu,et al.  PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[44]  David A. Price,et al.  Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover , 2007, The Journal of experimental medicine.

[45]  S. Stohlman,et al.  Impaired T Cell Immunity in B Cell-Deficient Mice Following Viral Central Nervous System Infection1 , 2001, The Journal of Immunology.

[46]  M. V. von Herrath,et al.  Evidence for an Underlying CD4 Helper and CD8 T-Cell Defect in B-Cell-Deficient Mice: Failure To Clear Persistent Virus Infection after Adoptive Immunotherapy with Virus-Specific Memory Cells from μMT/μMT Mice , 1998, Journal of Virology.

[47]  Klaus Rajewsky,et al.  A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin μ chain gene , 1991, Nature.

[48]  G. Vanham,et al.  Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  F. Guarnieri,et al.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.

[50]  N. Van Rooijen,et al.  Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study. , 1984, Cell and tissue research.